Last update July 26, 2024
Likely Compatibility
We do not have alternatives for Lenacapavir, Lenacapavir Sodium (LEN).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Lenacapavir, Lenacapavir Sodium (LEN) in other languages or writings:
Lenacapavir, Lenacapavir Sodium (LEN) belongs to this group or family:
Main tradenames from several countries containing Lenacapavir, Lenacapavir Sodium (LEN) in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 6 - 10 | % |
Molecular weight | 968 | daltons |
Protein Binding | 99.8 | % |
VD | 13.9 | l/Kg |
pKa | 6.69 | - |
Tmax | 4 | hours |
T½ | 240 - 288 | hours |
We are working to add the scientific references of this product. It will be available soon. If you wish to have access to this information, please let us know by leaving your comment in the opinion section below.
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Lenacapavir is an HIV-1 capsid inhibitor with antiviral activity against HIV-1. It is used with other antiretrovirals for the treatment of multidrug-resistant HIV-1 infection. Oral or subcutaneous administration. It has been approved in 2022 by the EMA and FDA.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (high molecular weight, very high percentage of binding to plasma proteins and very large volume of distribution) make it unlikely to pass into breast milk in clinically significant quantities.
Its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.
"Individuals with HIV who are on ART with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision". (Panel 2023 E-11)
See below the information of this related product: